VIR Vir Biotechnology, Inc.
Healthcare$9.38+2.07%ClosedMarket Cap: $1.58B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.67
P/S
23.66
EV/EBITDA
-3.05
DCF Value
$-71.71
FCF Yield
-28.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
275.2%
Operating Margin
-704.9%
Net Margin
-676.0%
ROE
-53.3%
ROA
-43.2%
ROIC
-48.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $-29.0K | 9793.1% | $-133.2M | $-125.7M | $— | — |
| Q4 null | $64.1M | 672.1% | $-36.6M | $-42.9M | $— | — |
| FY null | $68.6M | 82.9% | $-468.0M | $-438.0M | $— | — |
| Q3 null | $240.0K | -63005.0% | $-173.4M | $-163.1M | $— | — |
| Q2 null | $1.2M | -7932.9% | $-118.4M | $-111.0M | $— | — |
| Q1 null | $3.0M | -3779.1% | $-139.5M | $-121.0M | $— | — |
| Q4 null | $12.4M | -617.5% | $-117.2M | $-104.6M | $— | — |
| FY null | $74.2M | -545.0% | $-587.2M | $-522.0M | $— | — |
| Q3 null | $2.4M | -8102.9% | $-231.3M | $-213.7M | $— | — |
| Q2 null | $3.1M | -3320.0% | $-158.6M | $-138.4M | $— | — |
| Q1 null | $56.4M | -74.8% | $-80.1M | $-65.3M | $— | — |
| Q4 2023 | $16.8M | -533.6% | $-139.0M | $-116.0M | $-0.86 | — |